Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By Sue Sutter
Man climbing mountain.
Stealth faces a steep hill at the FDA cardio-renal adcomm on elamipretide. (Shutterstock)

More from US Advisory Committees

More from Rare Diseases